FAQ · 06
BPC-157 TB-500, answered from the literature
Twenty-five questions on the Wolverine blend — definitional, mechanistic, safety, dosing, and regulatory — each answered directly and cited where the claim is quantitative.
Identity and definitions
The first set of BPC-157 TB-500 questions is definitional: what the blend is, what each constituent is, and how the two differ.
Mechanism and evidence
These questions cover how each peptide works, whether they act through the same pathway, and what the combination evidence actually shows.
Safety questions
The safety questions are answered honestly against a thin record: there is no controlled human safety dataset for the blend, and one preclinical signal — tumor angiogenesis — is worth naming.
Dosing, half-life, and handling
These answers are research-context only. They report study parameters and handling practice, never human dosing guidance. Full detail sits on BPC-157 TB-500 dosage in the research literature.
Regulatory and access
The regulatory answers reflect the present-tense FDA record. Full context, cited to FDA, is on Wolverine legal status and FDA 503A compounding access.